ALKERMES | ALKS - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 1000K 2026-06
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
ALKERMES USD 1.81B 57.02M 2026-06
Amgen USD 11.69B 6.9B 2026-06
Biogen USD 2.32B 663.6M 2026-09
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Bristol-Myers Squibb USD 23.4B 1.08B 2026-09
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 13.04B 9.09B 2026-09
Heron Therapeutics USD 40.55M 1.46M 2025-12
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
J&J USD 18.93B 1.09B 2026-09
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 10.75B 5.02B 2026-09
Minerva Neurosciences USD 4.52M 155.46K 2024-12
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Otsuka Holdings JPY 561.64B 49.51B 2026-06
Ovoca Bio EUR 173K 990K 2025-12
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 33.5B 1.79B 2026-09
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06